Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Summary

Glenmark Pharmaceuticals announced the launch of Sugammadex Injection in two single-dose vial strengths (200 mg/2 mL and 500 mg/5 mL). The product is bioequivalent to reference formulations.